Edgewise Therapeutics Inc. saw its stock leap nearly 23% in pre-open trading after announcing a definitive agreement to sell its muscular dystrophy business to Servier, the independent French pharmaceutical group, for aggregate consideration of up to $2.65 billion.
Under the terms of the deal, Servier will obtain full ownership of sevasemten and the related muscular dystrophy program in return for $1.55 billion in immediate cash and as much as $1.1 billion in additional payments tied to regulatory and commercial milestones. The boards of directors of both companies gave unanimous approval to the transaction.
Edgewise said the agreement materially improves its balance sheet and narrows the company’s strategic focus. After the transaction closes, the company will realign as a cardiovascular-focused biopharma with a portfolio centered on EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for heart failure with preserved ejection fraction, and EDG-003.
Management emphasized that the upfront proceeds, when combined with existing cash on hand, are expected to fully fund EDG-7500 development through potential regulatory approval. Edgewise also reaffirmed its timeline, stating it remains on track to report 12-week CIRRUS-HCM Part D data in the second quarter of 2026 and targeting a Phase 3 launch for EDG-7500 in the fourth quarter of 2026.
The companies indicated the transaction is expected to close in the third quarter of 2026, subject to satisfaction or waiver of customary closing conditions.
Market context highlighted that the broader U.S. equity market provided only mild support the day the news broke, with the S&P 500 up 0.2%, the Dow Jones Industrial Average up 0.7% and the NASDAQ up 0.2%. Those modest gains were far too small to explain Edgewise’s outsized pre-market move, underlining that the stock’s jump was driven by company-specific news.
Analysts and market participants pointed to three primary drivers behind the re-rating: a significant immediate cash infusion, the removal of near-term funding uncertainty for the cardiovascular pipeline, and the clarity of a refocused corporate strategy as a pure-play cardiovascular company. The transaction also concretizes the value of sevasemten after several positive clinical and pipeline milestones in recent months.
In pre-market trading following the announcement, Edgewise climbed above its prior 52-week high of $39.96 and reached a new pre-market peak of $42.
Summary of key corporate points:
- Transaction value - up to $2.65 billion in aggregate consideration.
- Upfront cash - $1.55 billion, with up to $1.1 billion in regulatory and commercial milestone payments.
- Strategic refocus - post-close company concentrated on cardiovascular assets EDG-7500, EDG-15400, and EDG-003.
- Development financing - upfront proceeds plus existing funds expected to fully finance EDG-7500 through potential approval.
- Regulatory and development timeline - 12-week CIRRUS-HCM Part D data expected in Q2 2026; Phase 3 launch targeted for Q4 2026.
- Expected closing - third quarter of 2026, subject to customary closing conditions.